(Reuters) – Catalent (NYSE:) announced on Friday that it was unable to meet the deadline for filing its annual report with regulators due to the need for additional time to complete certain processes.
The contract drug manufacturer was supposed to submit the report on August 29th.
The company is currently awaiting the completion of the $16.5 billion acquisition deal that was signed in February by Novo Holdings, the investment firm with a controlling stake in Danish drugmaker Novo Nordisk (NYSE:).
Catalent anticipates the deal to be finalized towards the end of the year.
Catalent specializes in fill-finish work as a contractor, which involves the filling and packaging of syringes and injection pens in sterile conditions, including Novo Nordisk’s popular drug Wegovy.
In May, the U.S. Federal Trade Commission requested additional information regarding the deal after Novo Holdings submitted an application seeking approval from the antitrust agency.
On Thursday, the company surpassed analysts’ expectations for fourth-quarter revenue, driven by its biologics segment that focuses on the development and manufacturing of cell and gene therapies.